Literature DB >> 2095347

Stereoselectivity of cholinesterase inhibition by galanthamine and tolerance in humans.

T Thomsen1, U Bickel, J P Fischer, H Kewitz.   

Abstract

The effect of galanthamine (GAL) and its 2 major metabolites on human cholinesterases has been explored. Epigalanthamine, a diastereomer of GAL, was 130-times less potent in vitro in its effect on acetylcholinesterase (AChE) in erythrocytes than the parent compound, and it did not differ significantly from the ketone galanthaminone. In vivo, the maximal 36-55% inhibition of AChE was approached 30 min after oral administration of 10 mg GAL. The duration of the catalytic inhibition corresponded to an elimination half-life of approximately 5-7 h. GAL was well tolerated in 8/8 healthy volunteers, and 3/4 Alzheimer patients tolerated the drug up to a daily dose of 40 mg.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2095347     DOI: 10.1007/bf00316106

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  8 in total

1.  A suitable method to monitor inhibition of cholinesterase activities in tissues as induced by reversible enzyme inhibitors.

Authors:  T Thomsen; H Kewitz; O Pleul
Journal:  Enzyme       Date:  1989

2.  Reversed-phase liquid chromatography for the determination of galanthamine and its metabolites in human plasma and urine.

Authors:  J Tencheva; I Yamboliev; Z Zhivkova
Journal:  J Chromatogr       Date:  1987-10-30

3.  The interaction of human cholinesterases with anticholinesterases used in the therapy of myasthenia gravis.

Authors:  F F Foldes; J C Smith
Journal:  Ann N Y Acad Sci       Date:  1966-01-26       Impact factor: 5.691

4.  Estimation of cholinesterase activity (EC 3.1.1.7; 3.1.1.8) in undiluted plasma and erythrocytes as a tool for measuring in vivo effects of reversible inhibitors.

Authors:  T Thomsen; H Kewitz; O Pleul
Journal:  J Clin Chem Clin Biochem       Date:  1988-07

5.  Pharmacokinetics of galanthamine hydrobromide after single subcutaneous and oral dosage in humans.

Authors:  D Mihailova; I Yamboliev; Z Zhivkova; J Tencheva; V Jovovich
Journal:  Pharmacology       Date:  1989       Impact factor: 2.547

6.  Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo.

Authors:  T Thomsen; H Kewitz
Journal:  Life Sci       Date:  1990       Impact factor: 5.037

7.  Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.

Authors:  G McKhann; D Drachman; M Folstein; R Katzman; D Price; E M Stadlan
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

8.  [On the molecular mechanism of action of galanthamine, an antagonist of nondepolarizing muscle relaxants (author's transl)].

Authors:  F T Schuh
Journal:  Anaesthesist       Date:  1976-09       Impact factor: 1.041

  8 in total
  7 in total

Review 1.  The pharmacological landscape and therapeutic potential of serine hydrolases.

Authors:  Daniel A Bachovchin; Benjamin F Cravatt
Journal:  Nat Rev Drug Discov       Date:  2012-01-03       Impact factor: 84.694

Review 2.  Galantamine: a review of its use in Alzheimer's disease.

Authors:  L J Scott; K L Goa
Journal:  Drugs       Date:  2000-11       Impact factor: 9.546

Review 3.  Galanthamine.

Authors:  B Fulton; P Benfield
Journal:  Drugs Aging       Date:  1996-07       Impact factor: 3.923

4.  Galanthamine in Alzheimer's disease : a new alternative to tacrine?

Authors:  M Rainer
Journal:  CNS Drugs       Date:  1997-02       Impact factor: 5.749

Review 5.  Clinical pharmacokinetics of galantamine.

Authors:  Martin R Farlow
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 6.  Galantamine for Alzheimer's disease and mild cognitive impairment.

Authors:  C Loy; L Schneider
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25

7.  A critical review of cholinesterase inhibitors as a treatment modality in Alzheimer's disease.

Authors:  L S Schneider
Journal:  Dialogues Clin Neurosci       Date:  2000-06       Impact factor: 5.986

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.